ClinicalTrials.gg
CompletedNCT03282513Updated Apr 27, 2018

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

A Phase 1 interventional study of AG-120 (Ivosidenib) in Hepatic Impairment, sponsored by Agios Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-27.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Study AG120-C-012 is a Phase 1, open-label, single-dose study designed to evaluate the PK, safety, and tolerability of a single 500 mg AG-120 (Ivosidenib) dose in subjects with mild or moderate hepatic impairment (HI) compared to subjects with normal hepatic function. The study will be conducted at 2 US centers.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • AG-120
  • Healthy Volunteer
  • Clinical Pharmacology
  • Hepatic Impairment
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

All subjects:

  • BMI of 19 to 40 kg/m2 (inclusive).
  • Willing and able to comply with all study restrictions and requirements.
  • Non- smoker, or uses no more nicotine-containing product than the equivalent of smoking ≤10 cigarettes per day, as judged by the investigator.
  • Female subjects must be non pregnant and non-lactating and either be , surgically sterile, practice total abstinence from sexual intercourse as the preferred lifestyle or agree to use an appropriate method of consistently throughout the study, from screening until 90 days after study drug administration.
  • Male subjects with a partner of child bearing potential must either be sterile, practice total abstinence from sexual intercourse as the preferred life style or agree to use an appropriate method of birth control consistently throughout the study, from screening until 90 days after study drug administration.

Subjects with hepatic impairment (Cohorts 1a, 2a)

  • Diagnosis of chronic (≥3 months prior to Screening) or stable (no acute episodes of illness within 2 months prior to Screening due to deterioration in hepatic function) hepatic insufficiency, with a classification score in the mild or moderate range.
  • Hepatic insufficiency may be of any etiology associated with an unambiguous medical history (such as evidence of portal hypertension).
  • Other than hepatic insufficiency with features of cirrhosis, subjects are in good health based on medical history, physical exam, , clinical laboratory tests, and Investigator's assessment.

Healthy matched subjects (Cohorts 1b, 2b)

  • Have normal hepatic function and considered by the Investigator to be in good health, based on medical and surgical history review, physical exam, ECG, clinical laboratory tests, and Investigator's assessment.

Key Exclusion Criteria:

All subjects:

  • Significant acute, new-onset illness (eg, flu, gastroenteritis) within 2 weeks prior to dosing.
  • Positive test for drugs of abuse and/or positive alcohol test at Screening or prior to dosing.
  • Medical history of ECG abnormalities or a family history of prolonged syndromes.
  • History of immunocompromise, including positivity for , or active viral or C.
  • Use of over the counter (OTC) medications, herbal supplements, grapefruit juice, Seville oranges, or vitamins 14 days prior to dosing.
  • A recent (within 6 months prior to dosing) history of acute or chronic bronchospastic disease, including asthma and .
  • Current or history of hepatic carcinoma, hepatorenal syndrome, portacaval shunt surgery, or pleural effusion. , including leukemia and lymphoma, within the last 5 years.
  • Any surgical or medical condition that might significantly alter the absorption, distribution, or excretion of AG-120.
  • Treatment with strong cytochrome P450 (CYP)3A4 inhibitors or inducers within 14 days prior to AG 120 dosing or during the study.

Subjects with hepatic impairment (Cohorts 1a, 2a)

  • Clinical evidence of moderate to severe ascites.
  • Significant history or clinical manifestation of any significant metabolic/endocrine, allergic, dermatologic, renal, hematologic, pulmonary, immune, cardiovascular, gastrointestinal, genitourinary, neurologic, or psychiatric disorder, as determined by the Investigator and/or Sponsor's medical monitor (MM) to be clinically significant (CS.)
  • Any evidence of progressive liver disease (within the last 4 weeks prior to dosing)
  • Severe or uncontrolled medical conditions within 4 weeks prior to AG-120 dosing, with the exception of illness related to HI.

Healthy Matched Subjects

  • Clinical evidence of liver disease or liver injury
  • History or presence of impaired renal function
  • QTCF >450 (males) or >460 (females) or ECG findings deemed abnormal by the Investigator
  • Use of any prescription medications within 30 days prior to dosing
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Cohort 1A: Mild Hepatic Impairment

    Drug: AG-120 (Ivosidenib) A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with mild hepatic impairment(Child-Pugh Score A.)

    Drug: AG-120 (Ivosidenib)

  • Active comparator
    Cohort 1B: Healthy Volunteers

    Drug: AG-120 (Ivosidenib) A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function.

    Drug: AG-120 (Ivosidenib)

  • Experimental
    Cohort 2A: Moderate Hepatic Impairment

    Drug: AG-120 (Ivosidenib) A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with moderate hepatic impairment (Child-Pugh Score B.)

    Drug: AG-120 (Ivosidenib)

  • Active comparator
    Cohort 2B: Healthy Volunteers

    Drug: AG-120 (Ivosidenib) A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function.

    Drug: AG-120 (Ivosidenib)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    AG-120 Cmax, derived from plasma concentration-time curves

    Time frame: Predose; 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 9hr, 12hr, 24hr, 48hr, 72hr, 120hr, 168hr, 240hr, 336hr, and 504hr post dose

  2. Area under plasma concentration-time curve (AUC)

    AG-120 AUC, derived from plasma concentration-time curves

    Time frame: Predose; 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 9hr, 12hr, 24hr, 48hr, 72hr, 120hr, 168hr, 240hr, 336hr, and 504hr post dose

Secondary outcomes

  1. Adverse Events (AE) and treatment-related AE

    Time frame: From the time of study drug administration through the end of study (Day 29 or early termination)

  2. Plasma Protein Binding

    Compare the plasma protein binding of AG-120 (Ivosidenib) in subjects with impaired HI with that in subjects with normal hepatic function.

    Time frame: Time Frame: Pre-dose, Day 1 and Day 2

07

Study locations

2 sites
  • DaVita Clinical Research- Colorado
    Lakewood, Colorado 80228, United States
  • DaVita Clinical Research- Minnesota
    Minneapolis, Minnesota 55404, United States
08

References and documents

Publications

  • Fan B, Dai D, Cohen M, Xu H, Yin F, Nagaraja R, Mobilia M, Almon C, Basile FG, Yang H. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan;10(1):99-109. doi: 10.1002/cpdd.821. Epub 2020 Jul 9. PubMed 32648303 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Mar 2018, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2017
First posted
Sep 14, 2017
StartActual
Sep 26, 2017
Primary completionActual
Mar 31, 2018
CompletionActual
Mar 31, 2018
Last update
Apr 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03282513
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Sep 26, 2017
Primary completion
Mar 31, 2018
Completion
Mar 31, 2018
Last update
Apr 27, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivosidenib

Start the discussion